PBLS

Parabilis Medicines Inc

25.35

Oct 19 • 3:59 PM ET +2.60 (11.43%)

25.32

Aftermarket • 7:51 PM ET -0.03 (-0.12%)

Healthcare Biotechnology USA Mid NASD

Today, 11:02 AMMonday's fresh ESMO zolucatetide readout details lift Parabilis 13% during regular trading

Peers: RLAY IMNM IDYA TNGX ERAS RVMD KYMR CELC ELVN ARVN

| Held by: VTI VB IWM VBR VXF VTWO IWO SCHA IWN ITOT

Scroll to Statements

Index	RUT
Market Cap	3.13B
Enterprise Value	2.06B
Income	-
Sales	-
Book/sh	8.48
Cash/sh	9.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jun 10, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.99
P/C	2.79
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	17.91
Current Ratio	17.91
Debt/Eq	0.05
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.36
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-1306.06% -99.40%

Insider Own	37.28%
Insider Trans	91.18%
Inst Own	50.95%
Inst Trans	120.65%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-14.12%
SMA50	-27.35%
SMA200	-22.56%
Trades

Shs Outstand	121.94M
Shs Float	77.48M
Short Float	10.66%
Short Ratio	11.27
Short Interest	8.26M
52W High	42.49 -40.33%
52W Low	22.66 11.87%
Volatility	10.21% 10.04%
ATR (14)	2.66
RSI (14)	35.25
Beta	-
Rel Volume	2.92
Avg Volume	733.35K
Volume	2,142,690

Perf Week	-12.44%
Perf Month	-39.25%
Perf Quarter	-15.61%
Perf Half Y	-
Perf YTD	-23.99%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	41.75
Prev Close	22.75
Price	25.35
Change %	11.43%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-06-26	Initiated	Leerink Partners	Outperform	$40
Jul-06-26	Initiated	Guggenheim	Buy	$40
Jul-06-26	Initiated	Evercore ISI	Outperform
Jul-06-26	Initiated	BofA Securities	Buy	$45

Today 07:00AM	Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026 (GlobeNewswire) +11.43%
Oct-14-26 07:00AM	Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis (GlobeNewswire)
Sep-01-26 07:00AM	Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-25-26 07:00AM	Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors (GlobeNewswire)
Aug-24-26 08:01PM	Young startups miss out on biotech venture funding rebound, MassBio says (BioPharma Dive)
07:07AM	Loading…
Aug-13-26 07:07AM	Parabilis Medicines: Q2 Earnings Snapshot (Associated Press)
07:00AM	Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-07-26 01:15AM	These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks (Barrons.com)
Jun-11-26 04:05PM	Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -10.06%
Jun-09-26 08:22PM	Parabilis Medicines Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

Ph.D.Dr. Mathai Mammen M.D.

Executive VPMs. Teresa L. Jurgensen J.D.

Scientific Co-FounderMr. John McGee Ph.D.

Chief Financial OfficerMr. Thomas Rodolpho Kotarakos

Chief Technical Operations OfficerDr. Rohin Mhatre Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 20 '26	Buy	27.28	131,420	3,584,887	26,416,513	Jul 22 04:55 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 21 '26	Buy	29.25	65,923	1,928,032	26,482,436	Jul 22 04:55 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 22 '26	Buy	29.77	47,250	1,406,632	26,529,686	Jul 22 04:55 PM
Levy Guy	10% Owner	Jun 11 '26	Buy	20.00	500,000	10,000,000	1,027,000	Jun 29 10:41 AM
SEBULSKY ALAN	Director	Jun 15 '26	Buy	26.49	9,065	240,135	30,000	Jun 16 06:19 PM
SEBULSKY ALAN	Director	Jun 12 '26	Buy	27.67	8,435	233,393	20,935	Jun 16 06:19 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 11 '26	Buy	20.00	21,188,750	423,775,000	26,285,093	Jun 15 06:57 PM
SEBULSKY ALAN	Director	Jun 11 '26	Buy	20.00	12,500	250,000	12,500	Jun 15 05:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PBLS

Parabilis Medicines Inc

Upgrade your Finviz experience